NCT07449377Recruiting
Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Acute heart failure (AHF) is a major cause of acute dyspnea in emergency departments (EDs), driven primarily by venous congestion, which can lead to hepatic congestion and risk of subsequent liver dysfunction. Current diagnostic tools include clinical evaluation, biomarkers, and imaging (Chest X-Ray or echography), are often limited by delayed results, variability, and suboptimal accuracy in emergency settings. Fibroscan®, a non-invasive device originally designed to assess liver stiffness in chronic liver conditions, has shown potential in detecting liver congestion linked to heart failure. Studies have highlighted significant correlations between liver stiffness measurements (LSM) and markers of venous congestion, such as central venous pressure and adverse outcomes in heart failure patients. Preliminary findings suggest that LSM could provide rapid, bedside insights into systemic congestion, offering a promising avenue for improving diagnostic workflows in acute care. While prior research has mainly focused on chronic heart failure or small study populations, further investigation is needed to explore the utility of Fibroscan® in acute presentations of AHF within EDs. This could help address the limitations of existing diagnostic approaches and enhance patient management in time-sensitive environments.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 27 Feb 2026
- Start date
- 2 Apr 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Heart failure
- NCT number
- NCT07449377
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 2 Apr 2026 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known chronic liver disease, defined by a Prothrombic time of \< 50%, or any former diagnosis of liver fibrosis.
- History of liver transplantation
Lab values
- eGFR \<30 mL/min
Other
- No skin wounds in the abdominal area on which the Fibroscan® will be used
- Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom
- Pregnancy and breastfeeding
- Participation in another interventional trial
Who the study is looking for
- Patients ≥18 years
- ED patients presenting with acute dyspnea and absence of any other obvious cause of dyspnea (for example pneumothorax, acute pneumonia, acute coronary syndrome, Covid) …
- Social security affiliation (except AME)
- Informed consent signed
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Name: Emergency Department Hospital Pitié-Salpêtrière, APHP Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.